Literature DB >> 23073851

The expression and function of microRNA-203 in lung cancer.

Jianhua Jin1, Jianzhong Deng, Fang Wang, Xiyi Xia, Tiefeng Qiu, Wenbin Lu, Xianwen Li, Hua Zhang, Xiaoyan Gu, Yungang Liu, Weiguo Cao, Wenlong Shao.   

Abstract

We aimed to determine the expression of microRNA-203 (miR-203) in human lung cancer cell lines and to evaluate the effects of miR-203 by targeting survivin, on the lung cancer cell line 95-D to provide potential new strategies for treating lung cancer. The expression of miR-203 was detected using quantitative real-time PCR (qRT-PCR) in the in vitro cultured lung cancer cells A549, HCC827, NCI-H1299, and 95-D as well as in normal human bronchial epithelial cells. Following a 72-h transfection with the miR-203 precursor in 95-D lung cancer cells, the change in miR-203 expression was detected using qRT-PCR and the resulting effect on survivin protein expression was ascertained by Western blot analysis. The influence of miR-203 on the viability of 95-D lung cancer cells was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. The effect of miR-203 on 95-D cell proliferation was analyzed using flow cytometry. The consequences of miR-203 expression on 95-D cell apoptosis were analyzed by Annexin V/propidium iodide double staining coupled with flow cytometry. The role of miR-203 in the invasive potential of 95-D cells was studied using a transwell chamber assay. A luciferase reporter gene system was used to verify that survivin is a target gene for miR-203. By qRT-PCR, the expression of miR-203 was lower in lung cancer cells than in normal bronchial epithelial cells (p < 0.01), and the expression of miR-203 in 95-D lung cancer cells was significantly higher after a 72-h transfection with the miR-203 precursor (p < 0.01). After a 72-h transfection with the miR-203 precursor, survivin protein levels in 95-D cells were significantly decreased (p < 0.01). Cell viability, as assessed with an MTT assay, decreased following an increase in miR-203 expression (p < 0.05). The flow cytometry results indicated that after miR-203 expression increased, the cell proliferation index decreased (p < 0.05) and the number of apoptotic cells increased (p < 0.01). Increased miR-203 expression led to a significant decrease in the number of cells that migrated through a transwell chamber membrane (p < 0.01). The luciferase reporter gene system demonstrated that the relative luciferase activity significantly decreased after transfection with the miR-203 precursor (p < 0.05). The expression of miR-203 is downregulated in lung cancer cells. miR-203 negatively regulates survivin protein expression and inhibits the proliferation and invasion of lung cancer cells. Therapeutic strategies that enhance miR-203 expression or silence survivin could potentially benefit lung cancer patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23073851     DOI: 10.1007/s13277-012-0556-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  41 in total

1.  Colorectal cancer screening using protected microRNAs.

Authors:  Nathan R Wall
Journal:  J Gastrointest Oncol       Date:  2011-12

2.  Delays in the diagnosis of lung cancer.

Authors:  Peter M Ellis; Rachel Vandermeer
Journal:  J Thorac Dis       Date:  2011-09       Impact factor: 2.895

3.  Drosha regulates neurogenesis by controlling neurogenin 2 expression independent of microRNAs.

Authors:  Philip Knuckles; Miriam A Vogt; Sebastian Lugert; Marta Milo; Mark M W Chong; Guillaume M Hautbergue; Stuart A Wilson; Dan R Littman; Verdon Taylor
Journal:  Nat Neurosci       Date:  2012-06-17       Impact factor: 24.884

4.  MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma.

Authors:  Naoki Ikenaga; Kenoki Ohuchida; Kazuhiro Mizumoto; Jun Yu; Tadashi Kayashima; Hiroshi Sakai; Hayato Fujita; Kohei Nakata; Masao Tanaka
Journal:  Ann Surg Oncol       Date:  2010-07-22       Impact factor: 5.344

Review 5.  Survivin in solid tumors: rationale for development of inhibitors.

Authors:  David N Church; Denis C Talbot
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

Review 6.  Advances on EGFR mutation for lung cancer.

Authors:  Giulio Metro; Lucio Crinò
Journal:  Transl Lung Cancer Res       Date:  2012-03

7.  MicroRNAs and the Regulation of Tau Metabolism.

Authors:  Sébastien S Hébert; Nicolas Sergeant; Luc Buée
Journal:  Int J Alzheimers Dis       Date:  2012-06-05

8.  MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells.

Authors:  Chen Wang; Xiangqian Zheng; Chunyan Shen; Yurong Shi
Journal:  J Exp Clin Cancer Res       Date:  2012-06-19

9.  Changes of microRNAs-192, 196a and 203 correlate with Barrett's esophagus diagnosis and its progression compared to normal healthy individuals.

Authors:  Pavla Luzna; Jan Gregar; Ivo Uberall; Lenka Radova; Vlastimil Prochazka; Jiri Ehrmann
Journal:  Diagn Pathol       Date:  2011-11-17       Impact factor: 2.644

10.  Small RNA and its application in andrology and urology.

Authors:  Ji Wang; Long-Cheng Li
Journal:  Transl Androl Urol       Date:  2012
View more
  16 in total

1.  KLF5 activates microRNA 200 transcription to maintain epithelial characteristics and prevent induced epithelial-mesenchymal transition in epithelial cells.

Authors:  Baotong Zhang; Zhiqian Zhang; Siyuan Xia; Changsheng Xing; Xinpei Ci; Xin Li; Ranran Zhao; Sha Tian; Gui Ma; Zhengmao Zhu; Liya Fu; Jin-Tang Dong
Journal:  Mol Cell Biol       Date:  2013-10-14       Impact factor: 4.272

Review 2.  MicroRNA regulation and therapeutic targeting of survivin in cancer.

Authors:  Jingcao Huang; Hui Lyu; Jianxiang Wang; Bolin Liu
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

3.  Prognostic significance of microRNA-203 in cholangiocarcinoma.

Authors:  Jingjing Li; Beibei Gao; Zufa Huang; Tong Duan; Daiqiang Li; Sheng Zhang; Yujun Zhao; Lian Liu; Qiang Wang; Zhizhao Chen; Ke Cheng
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

4.  Potential roles of EZH2, Bmi-1 and miR-203 in cell proliferation and invasion in hepatocellular carcinoma cell line Hep3B.

Authors:  Fang Yang; Li-Zhi Lv; Qiu-Cheng Cai; Yi Jiang
Journal:  World J Gastroenterol       Date:  2015-12-21       Impact factor: 5.742

5.  Expression of miR-203 is decreased and associated with the prognosis of melanoma patients.

Authors:  Kai Wang; Zheng-Wen Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

6.  MicroRNA-203 regulates melanosome transport and tyrosinase expression in melanoma cells by targeting kinesin superfamily protein 5b.

Authors:  Shunsuke Noguchi; Minami Kumazaki; Yuki Yasui; Takashi Mori; Nami Yamada; Yukihiro Akao
Journal:  J Invest Dermatol       Date:  2013-07-22       Impact factor: 8.551

7.  MicroRNA-203 inhibits cellular proliferation and invasion by targeting Bmi1 in non-small cell lung cancer.

Authors:  Tengfei Chen; Chun Xu; Jun Chen; Cheng Ding; Zhenlei Xu; Chang Li; Jun Zhao
Journal:  Oncol Lett       Date:  2015-03-27       Impact factor: 2.967

8.  The prognostic value of microRNAs varies with patient race/ethnicity and stage of colorectal cancer.

Authors:  Liselle C Bovell; Chandrakumar Shanmugam; Balananda-Dhurjati K Putcha; Venkat R Katkoori; Bin Zhang; Sejong Bae; Karan P Singh; William E Grizzle; Upender Manne
Journal:  Clin Cancer Res       Date:  2013-05-29       Impact factor: 12.531

9.  Association between downexpression of MiR-203 and poor prognosis in non-small cell lung cancer patients.

Authors:  R Tang; T Zhong; Y Dang; X Zhang; P Li; G Chen
Journal:  Clin Transl Oncol       Date:  2015-08-26       Impact factor: 3.405

10.  Therapeutic intervention of silymarin on the migration of non-small cell lung cancer cells is associated with the axis of multiple molecular targets including class 1 HDACs, ZEB1 expression, and restoration of miR-203 and E-cadherin expression.

Authors:  Tripti Singh; Ram Prasad; Santosh K Katiyar
Journal:  Am J Cancer Res       Date:  2016-06-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.